Peter Chang, MD
Ophthalmology · Waltham, MANPI 1801107859
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $811,618 of the $992,201 with a category attached, or 81.8%. Mallinckrodt Hospital Products Inc. accounts for 61.4% of it on its own, with 43 other manufacturers making up the rest. Among ophthalmology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,171 payments — averaging $847.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Mallinckrodt Hospital Products Inc.$610K
- Eyepoint US, Inc.$134K
- Bausch & Lomb Americas Inc.$66K
- Regeneron Healthcare Solutions, Inc.$53K
- Alimera Sciences, Inc.$45K
- ANI Pharmaceuticals, Inc.$20K
- plus $64K from 38 others
Across 10 payments — averaging $5773.76 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eyepoint US, Inc.$25K
- Alimera Sciences, Inc.$20K
- AbbVie$8K
- Boehringer Ingelheim$4K
- Boehringer Ingelheim Pharma GmbH & Co.kg$935
What the payments were for
- Consulting fees$92,2859%
- Speaking & faculty fees$811,61882%
- Travel & lodging$52,9395%
- Food & beverage$35,2014%
- Education$1120%
- Gifts$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ACTHAR$599,600
- YUTIQ$152,645
- XIPERE$64,394
- EYLEA HD$51,982
- Iluvien$43,920
- PURIFIED CORTROPHIN GEL$16,614
- Clareon$12,949
- Izervay$12,447
- XOLREMDI$6,000
- Humira$5,882
- VABYSMO$4,463
- EYLEA$3,925
- EYP-1901$3,700
- SUSVIMO$2,624
- EVA, combined machine$1,581
- TISSUEBLUE$1,581
- DAILIES$1,221
- Implantable Miniature Telescope$334
- Rocklatan$247
- IHEEZO$185
How this compares
$992,201 in reported general payments places this provider in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ActharCorticotropin | 27 | $1,773,013 |
| OxervateCenegermin-Bkbj | 48 | $1,459,432 |
| Humira(Cf) PenAdalimumab | 55 | $399,747 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 17 | $358,312 |
| RemicadeInfliximab | 29 | $211,738 |
| Humira(Cf)Adalimumab | 11 | $74,927 |
| ActemraTocilizumab | 13 | $61,814 |
| RestasisCyclosporine | 41 | $46,803 |
| ProlensaBromfenac Sodium | 43 | $28,943 |
| LumiganBimatoprost | 43 | $27,898 |
| Bromfenac Sodium | 63 | $21,543 |
| XdemvyLotilaner | 11 | $20,385 |
| Mycophenolate Mofetil | 80 | $18,576 |
| XiidraLifitegrast | 16 | $18,056 |
| MieboPerfluorohexyloctane/Pf | 12 | $12,580 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Mallinckrodt Hospital Products Inc.Acthar | $609,690 | $1,773,01327 claims |
| Dompe US, Inc.Oxervate | $567 | $1,459,43248 claims |
| AbbVieHumira(Cf), Restasis, Lumigan, Combigan, Alphagan P | $8,535 | $159,805120 claims |
| Genentech, Inc.Actemra | $1,680 | $61,81413 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta | $66,262 | $36,64939 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $486 | $32,95562 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $375 | $20,38511 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $637 | $10,93711 claims |
| AlconSimbrinza | $14,683 | $5,75017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 ophthalmology providers in Massachusetts.
Other ophthalmology in Waltham
- Stephen AnesiWaltham$922K
- Jonathan TalamoWaltham$225K
- Nandini VenkateswaranWaltham$149K
- Charles FosterWaltham$24K
- Rishi SinghBoston$1.7M
- David LallySpringfield$328K
- Adam RogersBoston$316K
- Bonnie HendersonBoston$279K
- Mark LatinaReading$279K
- Dean EliottBoston$250K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.